Forgot Password?
Return to Course Listing

CME: Practice updates in treating advanced-stage gastric and gastroesophageal junction cancers


Activity Description / Statement of Need:

In this online, self-learning activity:

Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents.  This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

Target Audience:

HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.

This activity is free of charge.

Release Date: October 31, 2021 -- Expiration Date: October 31, 2022

Faculty: Yanghee Woo, MD


Faculty introduction and disclosures

Introductory content

·       Epidemiology

·       Risk factors [Learning Objective #1]

·       Clinical features, presentation, genetic testing

·       Diagnostic tools and criteria [Learning Objective #1]

Treatment of advanced GC and GEJC

·       Cytotoxic chemotherapy [Learning Objective #2]

·       Biomarkers’ evolving roles in guiding treatment [Learning Objective #3]

·       Current and emerging therapies, including targeted mechanisms: [Learning Objective #2]

o   Immunotherapy

o   PD-1 and PD-L1 inhibitors

o   CTLA-4

o   Adenocarcinomas

o   Trifluridine/tipiracil

o   VEGF-targeting agents

o   HER2-positive disease

o   Active areas of investigation: FGFR, PARP

·       Therapy schedule

·       Safety profiles of current and emerging agents

·       Managing comorbidities and adverse effects

·       Putting it all together: integrated, best practice

·       Patient case(s) [Learning Objective #4]

Summary, conclusions, and best practice recap

Learning Objectives

By the end of the session the participant will be able to:

  • Describe challenges in the risk assessment and identification of GC & GEJC.
  • Recall present and emerging treatment options for advanced GC & GEJC and monitoring parameters for effectiveness of treatment.
  • Summarize the present role of biomarkers in the prognosis and treatment of advanced GC & GEJC.
  • Formulate a safe and clinically effective treatment plan for patients with advanced GC & GEJC.
  • Describe the current status of epidemiology, treatment, and outcomes of GC


ACCME Activity #201762760


Faculty Disclosure and Resolution of COI

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

Faculty DisclosureYanghee Woo, MD, Associate Professor, City of Hope, Duarte, CA, has received financial compensation from Ethicon, J&J and Aureus for consulting work.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty will not discuss off-label uses.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from AMGEN.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care

Biosimilars in the treatment of malignancies and supportive care

Metastatic Colon Cancer: Updates from the 2020 ASCO (American Society of Clinical Oncology) Annual Meeting

Mesothelioma management Therapeutic updates and best practices